Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

Tuberculosis (TB) is a global public health problem exacerbated by the HIV epidemic. Here we evaluate a candidate TB vaccine, MVA85A, in a Phase I study in HIV-infected adults in Senegal. 24 patients were enrolled: Group 1∶12, antiretroviral therapy (ART) naïve, adults, with CD4 counts >300 and H...

Full description

Saved in:
Bibliographic Details
Main Authors: Tandakha N Dieye, Birahim P Ndiaye, Alle B Dieng, Marema Fall, Nathaniel Brittain, Samantha Vermaak, Makhtar Camara, Halimatou Diop-Ndiaye, Ndeye Fatou Ngom-Gueye, Papa A Diaw, Coumba Toure-Kane, Papa S Sow, Souleymane Mboup, Helen McShane
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0067177&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items